Trulieve Cannabis named for preliminary Russell 2000 and 3000 inclusion
FTSE Russell's next list update is Nov. 20, with membership changes scheduled to take effect after the Dec. 11 market close.

FTSE Russell published preliminary additions to its U.S. equity benchmarks on Nov. 13, with membership changes scheduled for Dec. 11. Trulieve Cannabis Corp. NYSETRLV said Monday it is in line to join the Russell 2000 and Russell 3000, subject to final membership.
The provider's preliminary Russell 3000 additions file names Trulieve under its NYSE symbol. Trulieve's Monday announcement says membership is scheduled to take effect after the Dec. 11 market close, rather than when the preliminary list appeared.
Trulieve is a medical cannabis grower and retailer operating across several U.S. states, including Florida and Georgia.
NYSETRLV closed at US$10.90 at 4:00 p.m. EST on Nov. 13, according to Google Finance. That close preceded Monday's company announcement and cannot measure its trading impact.
Index Membership Could Broaden Fund Exposure
Approximately US$12.5 trillion in investor assets are benchmarked to or invested in products based on the Russell U.S. indexes, FTSE Russell said in its Nov. 13 reconstitution announcement. That figure covers the index family and includes benchmarked assets, so it provides no estimate of purchases of Trulieve shares.
For holders, confirmed inclusion could bring demand from funds seeking to reproduce the benchmarks' holdings. Trulieve's announcement gives neither an index weight nor a forecast for fund purchases, leaving the scale of any such demand unquantified.
"Index inclusion raises awareness of Trulieve, ultimately leading to greater liquidity and access to institutional investors," Trulieve chief executive Kim Rivers said in Monday's release.
The Russell 2000 represents small-cap U.S. equities and forms part of the broader Russell 3000, as Trulieve explained in Monday's release. Prospective entry in both reflects those nested benchmarks; it does not establish two separate pools of incoming capital.
Read more: Strategy Inc to leave MSCI USA Index at November 30 close
FTSE Russell said its December review is the second under the semi-annual reconstitution schedule reintroduced in 2026. The provider ranks eligible securities by market capitalization and applies exchange and investability requirements before communicating preliminary additions and deletions.
FTSE Russell expects 125 companies to join the Russell 2000 in the December review, including 18 initial public offerings. Its Nov. 13 release places the large-cap/small-cap breakpoint at approximately US$5.8 billion as of Oct. 30.
NYSE Listing Preceded The Index Review
In its June 5 uplisting notice, Trulieve said NYSE trading was expected to begin June 10. Monday's release identifies the NYSE as its current listing venue and says the company has also domesticated to the United States.
The June notice said a restructuring and third-party investment had resulted in deconsolidation of operations in markets serving both medical and adult-use customers. The remaining consolidated operations then included 206 medical marijuana dispensaries.
Canadian cannabis peer Organigram Global Inc. TSEOGI NASDAQOGI identifies both Nasdaq and Toronto Stock Exchange listings in its Nov. 13 announcement. TSEOGI was quoted at C$1.18 at 4:00 p.m. EST on Nov. 13, according to Google Finance.
Read more: Organigram gets Nasdaq bid-price notice with May 2027 deadline
For a sector price reference, AdvisorShares Pure US Cannabis ETF NYSEARCAMSOS was quoted at US$3.72 at 8:00 p.m. EST on Nov. 13, according to Google Finance.
The next scheduled check is FTSE Russell's Nov. 20 list update, followed by updates on Nov. 27 and Dec. 4. Its FAQ also schedules an update on Dec. 11, when confirmed membership changes take effect after the U.S. market close.
Adrian Kessler






